Research and Markets: Gilenya (Multiple Sclerosis) – Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/njkqmx/gilenya_multiple) has announced the addition of the "Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022" report to their offering.

Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFN) agents: Bayer's Betaseron/Betaferon (IFN-1b), Biogen's Avonex (IFN-1a) and Merck's Rebif (IFN-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Novartis' Gilenya (fingolimod; FTY720) was the first FDA-approved, orally-administered DMT available for the treatment of MS. Gilenya is a synthetic analogue of the fungus Isaria sinclarii that was originally developed by Yoshitomi Pharmaceutical Industries (now part of Mitsubishi Tanabe Pharma Corporation). Novartis acquired the rights to the compound in 1997. Gilenya is a first-in-class sphingosine-1-phosphate (S1P) receptor modulator. The FDA approved Gilenya in 2010 as a first-line treatment for RRMS in the US to reduce relapses and delay the progression of disability. However, due to safety concerns with cardiac adverse events, Gilenya is only recommended as a second-line therapy in Europe and Canada, which limits its prescribing to patients who fail to respond optimally to first-line treatment options, who are often those with highly active RRMS. Gilenya was initially rejected by NICE for recommendation in the UK due to the high cost of therapy, although the decision was later reversed after Novartis agreed to lower the price of the drug. Gilenya is marketed by Mitsubishi Tanabe Pharma Corporation in Japan under the brand name Imusera.

Scope

- Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Gilenya including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Gilenya for the top ten countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India

For more information visit http://www.researchandmarkets.com/research/njkqmx/gilenya_multiple

Go here to see the original:
Research and Markets: Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022